Study design. Participants were instructed to follow a standardized lifestyle with fixed activities at fixed time points (making the bed, doing the dishes, 15-minutes standing, sitting at desk, or free time) to prevent differences between the 2 study conditions. Sleeping metabolic rate was measured by whole-room indirect calorimetry (Omnical, Maastricht Instruments, Maastricht, The Netherlands) during the first night, which was used for estimation of caloric requirements.
After waking up on the third study day, participants ingested a thermometer capsule (Equivital, Philips-Respironics, Murrysville PA, USA) to measure core-body temperature (CBT) for 24 hours. Due to early excretion of the capsule or technical failure, complete CBT measurements were obtained in 8 participants only. At 7 PM on day 3, participants underwent a blood draw, directly followed by a 30-minute resting indirect calorimetry measurement and a skeletal muscle biopsy (see below). During the sleep opportunity between day 3 and 4, we measured sleeping metabolic rate in the respiration chamber by whole-room indirect calorimetry (Omnical, Maastricht Instruments, Maastricht, The Netherlands). Activity levels during scheduled sleep were measured by a custom built analog ultrasound system (IDEE Maastricht University, Maastricht, The Netherlands) with continuous movement detection which is sampled and converted to a digital signal at 60 Hz. Data were averaged over a time span of 5 minutes. The implementation of the radar system has been described before (1).
On the fourth study day, participants were woken up at 6:45 AM. Starting at 7 AM, an intravenous cannula was placed in the antecubital vein, followed by a blood draw, indirect calorimetry and skeletal muscle biopsy, similar to the previous day. After the biopsy, a two-step hyperinsulinemic euglycemic clamp was performed to assess insulin sensitivity (see below). During this test, participants remained fasted. Directly after the clamp (which takes approximately 8 hours), participants were provided with a meal and were allowed to go home as soon as plasma glucose was stabilized.
In the misaligned period, breakfast, lunch, snack and dinner were served at 8 PM, 12:30 AM, 3 AM and 8 AM and consecutive sleep opportunities were scheduled from 11 AM until 7 PM. Blood drawing, indirect calorimetry and skeletal muscle biopsies were performed on day 4 at 7 AM (behavioral evening) and at 7 PM (behavioral morning). The two-step hyperinsulinemic euglycemic clamp started after the 7 PM biopsy.
Study meals. Standardized meals for two days before and during the study were prepared according to Dutch dietary guidelines (2) . Caloric requirements for consumption at home and the first evening of the study period were calculated by multiplying the resting metabolic rate, estimated using the Harris-Benedict formula (3), with an activity factor of 1.5. In addition, as it is difficult to predict the exact energy expenditure of the participants, additional snacks were provided to reach an energy intake equal to the resting metabolic rate multiplied by a factor of 1.7. Participants were allowed to eat these additional snacks directly after their meals, only if they were still hungry.
Indirect calorimetry. Calculations of energy expenditure and substrate oxidation were made with the assumption of a negligible protein oxidation (4, 5) .
Two-step hyperinsulinemic euglycemic clamp. A primed-continuous infusion of D-[6,6-
2 H2]glucose was given for two hours to determine baseline endogenous glucose production (EGP), glucose appearance (Ra) and glucose disposal (Rd) (6) . Blood was frequently sampled and glucose levels directly analyzed in arterialized blood. Glucose was co-infused at an appropriate rate to maintain euglycemia (~5.0 mmol/L). During the last 30 minutes of each step, substrate oxidation was measured by indirect calorimetry.
High resolution respirometry. For the 7 AM and 7 PM (pre-clamp) biopsies, part of the biopsy was immediately placed in ice-cold preservation medium (BIOPS, OROBOROS Instruments, Innsbruck, Austria) and used for measurement of mitochondrial oxygen consumption. For this analysis, intact muscle fibers were permeabilized and oxygen consumption rate was measured upon several substrates using high-resolution respirometry (Oxygraph, OROBOROS Instruments, Innsbruck, Austria). Substrates used to consecutively supplement muscle fibers during this assay were octanoylcarnitine (trace 1) or pyruvate (trace 2), as described previously (7) . Uncoupled respiration was assed using carbonylcyanide p-trifluoromethoxyphenylhydrazone (FCCP). The remaining part of the muscle biopsy was immediately frozen in melting isopentane and stored at -80°C until further analysis.
Structural components of the mitochondrial electron transport chain complexes were quantified by western blot analysis as previously described (8). Briefly, human muscle tissue was lysed in RIPA buffer and protein concentration was determined using the Bio-Rad RC/DC kit (Bio-Rad Laboratories, Veenendaal, The Netherlands). Equal amounts of protein were loaded on 12% TGX gels (Bio-Rad Laboratories) and proteins were transferred to nitrocellulose with the Trans-Blot Turbo transfer system (Bio-Rad Laboratories). Primary antibodies: a cocktail of mouse monoclonal antibodies directed against human OXPHOS (dilution 1:10,000; ab110411, Abcam, Cambridge, UK). The specific proteins were detected using secondary antibodies conjugated with IRDye800, and were quantified with the CLx Odyssey Near Infrared Imager (Li-COR, Westburg, Leusden, The Netherlands). The individual total intensity of Complex I, II, III, IV and V was quantified and is expressed in arbitrary units (AU).
Gene transcript quantification.
To minimize the variability in reference gene normalization, the geometric mean of three reference genes (RPL26, GUSB and CYPB) was used, which were previously demonstrated to be expressed robustly independent of time (8, 9). This geometric mean served as the internal reference for comparative gene expression analysis in the remainder of the study.
Microarray processing and data analysis. RNA quality was assessed using RNA 6000 nanochips on the Agilent 2100 bioanalyzer (Agilent Technologies, Amstelveen, the Netherlands). Sample labelling, hybridization to chips and image scanning was performed according manufacturer's instructions. Quality control and data analysis pipeline have been described in detail previously (10) . Briefly, normalized expression estimates of probe sets were computed by the robust multiarray analysis (RMA) algorithm (11) as implemented in the Bioconductor package affyPLM. Probe sets were redefined using current genome information according to Dai et al. (12) based on annotations provided by the Entrez Gene database, which resulted in the profiling of 29,526 unique genes (custom CDF v22). To evaluate whether samples could be separated based on their gene expression profiles, multilevel partial least squares-discriminant analysis (PLS-DA) was performed, as implemented in the package mixOmics (13) . Differentially expressed probe sets (genes) were identified by using linear models (package limma) and an intensity-based moderated paired t-statistic (14, 15) . By blocking on subject in the design matrix the crossover design of the study was taken into account. P-values were corrected for multiple testing by a false discovery rate (FDR) method (16) . Changes in gene expression were related to changes in pathways by gene set enrichment analysis (GSEA) (17) using the Bioconductor package fgsea (18) and the subset of metabolic and signalling pathways retrieved from the expert-curated Kyoto Encyclopedia of Genes and Genomes (KEGG) database (19) . Only gene sets consisting of more than 10 and fewer than 500 genes were taken into account, which resulted in the inclusion of 226 gene sets. A list of human PPAR targets genes was obtained from (20) . For each comparison, genes were ranked on their absolute t-value that was calculated by the empirical Bayes method (21) . Statistical significance of GSEA results was determined using 10,000 permutations. Results were visualized using the Bioconductor package clusterProfiler (22) . Microarray data have been submitted to the Gene Expression Omnibus GSE106800. Sleeping metabolic rate was measured in a whole-body room calorimeter and defined as the lowest energy expenditure during scheduled sleep during three consecutive hours (A). Respiratory Exchange Ratio (RER) during the same period is depicted in (B). As can be seen in (C), the increased metabolic rate during circadian misalignment was present during the entire sleeping period. Time is displayed as clock hours (misaligned time on upper axis). Data is expressed as mean ± SEM. * p < 0.05. Depicted is a scatterplot based on log (base 2) fold changes (group mean) between the timepoints 7 AM (reference time point) and 7 PM in the control and misaligned condition. Correlation line indicates that the majority of genes tend to have a reversed expression pattern in the misaligned condition, suggesting they only partly align to behavioral rhythm. Genes that are clock related and that are known to display a circadian rhythm are highlighted in red.
These genes tend to align into an opposite direction compared to the regression line suggesting they do not align to behavioral rhythm. (reference timepoint) to 7 PM in the control and misaligned condition were used to determine the change in pathway activity. Directionality of change in pathway activity (either activated or inhibited) is not taken into account. Pathways are ranked according to the normalized enrichment score (NES). A high NES score indicates changed activity of the pathway at 7 PM compared to 7 AM in either the control or misaligned condition. Pathway analysis was performed on the basis of the 226 metabolic and signaling pathway subset from the KEGG database. (B) Changes in gene expression of individual genes (group mean) from 7 AM in the control condition to 7 PM in the misaligned condition were used to determine the change in pathway activity by GSEA. A high NES score indicates changed activity of the pathway at 7 PM compared to 7 AM in either the control or misaligned condition. Pathway analysis was performed on the basis of the 226 metabolic and signaling pathway subset KEGG database.
